All quotes are in local exchange time. Get the latest BioLineRx Ltd BLRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.02. The company was founded in 2003 and is headquartered in Modi'in, Israel. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 Get daily stock ideas from top-performing Wall Street analysts. . Go Premium. BLRX Stock Latest News. Get short term trading ideas from the MarketBeat Idea Engine. The Barchart Technical Opinion widget shows you today's overally Barchart Opinion with general information on how to interpret the short and longer term signals. For the best MarketWatch.com experience, please update to a modern browser. On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. View the Bioline RX Ltd Sponsored ADR news and quotes for today, invesment news based on TipRanks market-leading research tools. 0.8601 0.0151 . 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. m.s.q. Membership Options Help Gift . The stock is currently down 15.1% year-to-date, down 12.7% over the past 12 months, and down 84.7% over the past five years. Our daily ratings and market update email newsletter. Currency in USD, Trade prices are not sourced from all markets. BioLineRx Ltd. (NASDAQ: BLRX ), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a notification letter from The Nasdaq Stock Market LLC . Our daily ratings and market update email newsletter. join the STCK.PRO community and discover the power of social financial news! The company is scheduled to release its next quarterly earnings announcement on Thursday, November 17th 2022. Privacy Notice, and 3 Reasons Another Shoe May Drop for Skechers. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma SA NewsTue, May 04, 2021 5 Comments biolinerx EPS beats by $1.06 SA NewsTue, Feb. 23, 2021 5 Comments DSS,. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. Earnings for BioLineRx are expected to decrease in the coming year, from ($0.53) to ($0.54) per share. 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. There are currently no items in this Watchlist. BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update. Only 1.10% of the stock of BioLineRx is held by insiders. BioLineRx has received no research coverage in the past 90 days. BioLineRx (NASDAQ:BLRX) has a market capitalization of $51.06 million. Maybe even as soon as this month. Intraday data delayed at least 15 minutes or per exchange requirements. See the latest BioLine Rx Ltd ADR stock price (NASDAQ:BLRX), related news, valuation, dividends and more to help you make your investing decisions. Get short term trading ideas from the MarketBeat Idea Engine. Bioline Rx Ltd - BLRX stock news. The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 6.00, with a high estimate of 19.00 and a low estimate of 4.00. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The volume of shares traded was 0.11 million, which is lower than the average volume over the last three months of 431.65K. How much is Biolinerx stock worth today? No News Available. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Get the Latest News and Ratings for Your Stocks, Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Something went wrong while loading Watchlist. BioLine RX Ltd. ADR BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. 2022-11-03 09:11 ET - News Release. The remaining $30 million will be made available in two additional tranches subject to achieving pre-specified milestones. BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that Upcoming Earnings . Receive BLRX Stock News and Ratings via Email, November 8, 2022|Weekly Investor Alerts (Ad). MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Real-time analyst ratings, insider transactions, earnings data, and more. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View BioLineRx Ltd BLRX investment & stock information. ( NASDAQ: BLRX) Biolinerx currently has 718,283,665 outstanding shares. Receive a free world-class investing education from MarketBeat. This includes ~13.64 million of BLRX's American Depository Shares (ADSs) and warrants. Have Watchlists? Strong Buy 1 / 5 Buy Hold Sell The man who picked Bitcoin in 2014 when it was trading for just $369 picked Ethereum in 2016 when it was trading for just $7, AND even warned his followers of the 2020 crash. BLRX) Historical Stock Chart . With Biolinerx stock trading at $0.83 per share, the total value of Biolinerx stock (market capitalization) is $40.14M. Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE). Corporations 7% Dividend Worth Trying On? 104.92. Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TEL AVIV, Israel, Sept. 19, 2022 -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a . BLRX, Biolinerx Ltd Adr - Stock quote performance, technical chart analysis, . Current Price $0.86 Target Price $10.08 1,072.1% Upside $0 $11 Bioline RX Stock Rating What analysts recommend for BLRX stock, on a scale from 1 (buy) to 5 (sell). In the past three months, BioLineRx insiders have not sold or bought any company stock. BLRX stock was up over 80% as of Friday morning. BioLineRx saw a increase in short interest in October. Bioline RX Ltd Sponsored ADR (BLRX) Gets a Buy from H.C. Wainwright PR Newswire 47d BLRX INVESTOR ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class. TEL AVIV, Israel, Nov. 4, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a. Over the past year the S&P 500 has fallen -11.08% while BLRX has fallen -62.64%. What is BioLineRx's stock price forecast for 2023? Sign in to your free account to enjoy all that MarketBeat has to offer. BLRX: Recent Sedar Documents: . For the upcoming trading day on Thursday, 3rd we expect BioLineRx Ltd. to open at $0.86, and during the day (based on 14 day Average True Range), to move between $0.786 and $0.93, which gives a possible trading interval of +/-$0.0738 (+/-8.59%) up or down from last closing price. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 12.4%. Sign in with Google Sign in with Facebook Sign in with Apple or. BLRX Stock Message Board for Investors. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Home . Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Get BioLineRx News Delivered to You Automatically. Webull offers BLRX stock news, real time Biolinerx news help you invest smart. On Wednesday, shares in BioLineRx (BLRX) rise 0.97% to close the day at $1.57. Management to hold a conference call at 10:00 a.m. EDT Tel Aviv, Israel, May 7, 2019 --- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2019 on. Whether youre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Copyright 2022 MarketWatch, Inc. All rights reserved. Markets; Tech; Media . See what's happening in the market right now with MarketBeat's real-time news feed. BioLineRx's stock is owned by many different retail and institutional investors. In-depth profiles and analysis for 20,000 public companies. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. The stock price of BioLineRx (BLRX) fell by over 30% intraday today. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The offer is expected to close on (or around) September 21. Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. BLRX. Message Board Total Posts: 74. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. Learn about financial terms, types of investments, trading strategies, and more. NasdaqCM - NasdaqCM Real Time Price. BLRX BioLineRx News . Follow BLRX. The stock price of BioLineRx (NASDAQ: BLRX) a late clinical-stage biopharmaceutical company focused on oncology is trading over 20% lower pre-market today. Shares of pre-commercial-stage biopharmaceutical company BioLineRx (NASDAQ:BLRX) have nosedived in today's trade after the announcement of a $15 million registered direct offering. Get daily stock ideas from top-performing Wall Street analysts. 3 Reasons Another Shoe May Drop for Skechers. Get BioLine RX Ltd (BLRX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 1M ago. Learn about the media coverage comparison. By creating a free account, you agree to our, 11 Ways to Prevent Debt from Ruining Your Retirement Goals, 3 Reasons Amazon Will Deliver Better 2023 Returns, Bulls Vs Bears: Mullen Automotive Short Interest Grows, A Turnaround is Brewing in Starbucks Stock, Palantir Falls Into The Hands Of Value Investors, The Analysts Cant Keep Up with Arista Networks Stock, These Are The Top 10 Holdings Of Jason Kritzer. Each headline receives a score ranging from 2 (good news) to -2 (bad news). My Portfolio. BLRX Stock Heads Up on Phase 3 Data In the press release, BioLineRx announced positive data from the GENESIS Phase 3 clinical trial. YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. View the Bioline RX Ltd Sponsored ADR news and quotes for today, invesment news based on TipRanks market-leading research tools. BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. One share of BLRX stock can currently be purchased for approximately $0.83. Receive a free world-class investing education from MarketBeat. On average, they anticipate the company's share price to reach $6.00 in the next year. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MARKET TRADE. Today's Range; 0.90 - 0.97; 52-Week Range; 0.84 - 3.15; Price % Chg. YTD-55.19%; Price % Chg. Last 4 Weeks-48.79%; 50-Day Avg. Biolinerx Ltd. Stock Price, News and Company Updates. Please log in to your account or sign up in order to add this asset to your watchlist. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. Real-time analyst ratings, insider transactions, earnings data, and more. The company was founded in 2003 and is headquartered in Modi'in, Israel. Internal Enforcement Officer, Gen. The P/E ratio of BioLineRx is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. $129.51m. The tranches are available for drawdown at BioLineRx's discretion at various time points through October 1, 2024. BioLineRx to Present at the 2020 Biotech Showcase. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Looking for new stock ideas? That average rating earns the stock an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple . PR Newswire. Full data from pharmacoeconomic study will be presented demonstrating significant cost benefits from using motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell . a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received a . 2021 is expected to be a huge year for penny stocks. Visit a quote page and your recently viewed tickers will be displayed here. To see all exchange delays and terms of use please see Barchart's disclaimer. Corporations 7% Dividend Worth Trying On? BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. NLS Real-Time Price. Full Story. . Compare Top Brokerages Here. BioLine RX Ltd stock quotes, company profile, news and forecasts from CNN Business. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The latest price target for BioLine Rx ( NASDAQ: BLRX) was reported by HC Wainwright & Co. on Tuesday, February 23, 2021. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View our full suite of financial calendars and market data tables, all for free. Read about BioLine Rx Ltd ADR (BLRX:XNAS) stock and today's latest news and financial updates. BioLineRx Ltd (NASDAQ: BLRX) entered into a $40 million non-dilutive secured debt financing agreement with Kreos Capital. Please log in to your account or sign up in order to add this asset to your watchlist. The average price target is $19.00 with a high forecast of $19.00 and a low forecast of $19.00. Edwards Life Sciences Stock Disaster Could Be Your Bounty, It Not All Bad News for Advanced Micro Devices Stock, After Doubling, First Solar May Keep Shining, 7 Small-Cap Stocks That Could Rocket Higher in 2023, 7 Cash Rich Stocks That Offer Safety in Any Market, 7 Streaming Stocks that Will Stand up to Streaming Fatigue, 7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed, 7 Railroad Stocks to Keep Your Portfolio Chugging Along, 7 Solar Stocks Leading the Clean Energy Boom, 7 Water Stocks to Buy as the World Dries Up, 7 Sports Betting Stocks to Buy for Their Long-Term Possibilities, 7 Stocks to Buy to Outrun Rising Interest Rates, 7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time, BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification, BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting, BLRX: Cast Off the Bowlines: Aphexda Commercialization, BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization - Yahoo Finance, BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization, Form 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.com, INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100000 to Contact the Firm - Business Wire, BioLineRx Announces $15 Million Registered Direct Offering - Yahoo Finance, EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation BLRX - Business Wire, BioLineRx stock slips on $15M securities offering - Seeking Alpha, BioLineRx Announces $15 Million Registered Direct Offering, BioLineRx (BLRX) Enters $40M Non-Dilutive Debt Financing Agreement with Kreos Capital - StreetInsider.com, BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer, BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital, New Therapeutics Options in Pancreatic Ductal Adenocarcinoma Pipeline as 40+ Key Companies are Working on Drug Profiles | DelveInsight - Yahoo Finance, BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization - Yahoo Finance, BioLine Rx (NASDAQ:BLRX) BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixa - Benzinga, BioLine Rx (NASDAQ:BLRX) BioLineRx Announces Submission Of New Drug Application To FDA For Motixafortid - Benzinga, BioLineRx Announces Submission Of Its First NDA - Quick Facts, BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization, Global Actinic Keratosis Treatment Market to Reach $10.08 Billion by 2027 at a CAGR of 10.61% - Yahoo Finance, BioLineRx falls 9% as costs increase in second quarter - Seeking Alpha, BioLineRx Tops Q2 EPS by 12c By Investing.com - Investing.com, view top-rated stocks among Wall Street analysts, Pennsylvania Real Estate Investment Trust (PEI).
House For Rent Waterfront Worcester, Additional Protocol Ii Citation, Grand Prairie High School Phone Number, Kotlin Function With Parameter, Unique Key In Entity Framework Code First, Current Weather Of Baltimore Md,
